Tumour necrosis factor alpha increases melphalan concentration in tumour tissue after isolated limb perfusion.
Several possible mechanisms for the synergistic anti-tumour effects between tumour necrosis factor alpha (TNF-alpha) and melphalan after isolated limb perfusion (ILP) have been presented. We found a significant sixfold increase in melphalan tumour tissue concentration after ILP when TNF-alpha was added to the perfusate, which provides a straightforward explanation for the observed synergism between melphalan and TNF-alpha in ILP.
de Wilt
J H
JH
Department of Surgical Oncology, University Hospital Rotterdam Dijkzigt/Daniel den Hoed Cancer Centre, The Netherlands.
ten Hagen
T L
TL
de Boeck
G
G
van Tiel
S T
ST
de Bruijn
E A
EA
Eggermont
A M
AM
D000818:Animals; D018906:Antineoplastic Agents, Alkylating / Q000493:pharmacokinetics*; D004195:Disease Models, Animal; D004357:Drug Synergism; D005121:Extremities; D008297:Male; D008558:Melphalan / Q000493:pharmacokinetics*; D009368:Neoplasm Transplantation; D009374:Neoplasms, Experimental / Q000378:metabolism*; D010477:Perfusion; D051381:Rats; D011914:Rats, Inbred BN; D014409:Tumor Necrosis Factor-alpha / Q000494:pharmacology*
D018906:Antineoplastic Agents, Alkylating; D014409:Tumor Necrosis Factor-alpha; D008558:Melphalan